Early Detection vs. Overdiagnosis: The ctDNA Screening Paradox

ctDNA is opening new possibilities for detecting cancer earlier, but greater sensitivity doesn't always mean better outcomes. Dr. Gabriela Rosu shares the promise and challenges of ctDNA screening, including the risks of false positives and overdiagnosis. Using BRCA mutations as an example, she explains why screening works best when results lead to clear, actionable decisions. The discussion in this article also highlights how ctDNA, genetic risk factors, imaging, and clinical data can work together to create smarter, more personalized approaches to cancer detection and prevention.